Povorcitinib Clinical Trials (2026): 16 Studies for Healthy Participants & Hidradenitis Suppurativa (HS)
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
16 Povorcitinib clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 6 indications (including Healthy Participants & Hidradenitis Suppurativa (HS)) and 4,744 total planned enrollment. 8 Phase 3 Povorcitinib trials and 3 Phase 2 are listed. 3 Povorcitinib clinical trials are actively recruiting at 81 U.S. sites across 28 states. Most recent activity: NCT07213973 (Mar 2028).
Where to Participate: All Povorcitinib Trial Sites in the U.S. (81 sites across 28 states)
Every actively recruiting Povorcitinibtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AL | Investigative Site US086 | Birmingham35244 | NCT06855498 | Map |
| AZ | Investigative Site US004 | Phoenix85006 | NCT06855498 | Map |
| AZ | Medical Dermatology Specialists Phoenix | Phoenix85006 | NCT07213973 | Map |
| AZ | Saguaro Dermatology | Phoenix85008 | NCT07213973 | Map |
| CA | Investigative Site US076 | Fountain Valley92708-3701 | NCT06855498 | Map |
| CA | Investigative Site US077 | Fremont94538 | NCT06855498 | Map |
| CA | Investigative Site US020 | Laguna Niguel92677 | NCT06855498 | Map |
| CA | Investigative Site US036 | Los Angeles90033 | NCT06855498 | Map |
| CA | Investigative Site US067 | Los Angeles90045 | NCT06855498 | Map |
| CA | Investigative Site US060 | Northridge91325 | NCT06855498 | Map |
| CA | Investigative Site US037 | Oakland94611 | NCT06855498 | Map |
| CA | Investigative Site US089 | Santa Monica90403 | NCT06855498 | Map |
| CT | Uconn Health | Farmington06030 | NCT07213973 | Map |
| FL | Investigative Site US002 | Boca Raton33486 | NCT06855498 | Map |
| FL | Investigative Site US062 | Coral Gables33134 | NCT06855498 | Map |
| FL | Investigative Site US084 | Coral Gables33146 | NCT06855498 | Map |
| FL | Investigative Site US017 | Hialeah33012 | NCT06855498 | Map |
| FL | Investigative Site US019 | Hollywood33021-6746 | NCT06855498 | Map |
| FL | Investigative Site US015 | Miami33136 | NCT06855498 | Map |
| FL | Skin Research of South Florida, Llc | Miami33173 | NCT07213973 | Map |
| FL | University of Miami Miller School of Medicine | Miami33136 | NCT07213973 | Map |
| FL | Investigative Site US072 | Miami Lakes33014 | NCT06855498 | Map |
| FL | Investigative Site US023 | North Miami Beach33162 | NCT06855498 | Map |
| FL | Investigative Site US029 | Ocala34470 | NCT06855498 | Map |
| FL | Investigative Site US001 | Tampa33615 | NCT06855498 | Map |
| FL | Investigative Site US005 | Tampa33613 | NCT06855498 | Map |
| FL | Investigative Site US035 | Tampa33607 | NCT06855498 | Map |
| FL | Trueblue Clinical Research | Tampa33607 | NCT07213973 | Map |
| FL | Investigative Site US066 | West Palm Beach33401 | NCT06855498 | Map |
| FL | Investigative Site US070 | West Palm Beach33401 | NCT06855498 | Map |
| GA | Investigative Site US051 | Marietta30060-1047 | NCT06855498 | Map |
| GA | Advanced Medical Research Pc | Sandy Springs30328 | NCT07213973 | Map |
| IL | Investigative Site US093 | Chicago60657 | NCT06855498 | Map |
| IL | Endeavor Health Medical Group | Skokie60077 | NCT07213973 | Map |
| IL | Investigative Site US039 | West Dundee60118 | NCT06855498 | Map |
| IN | Investigative Site US008 | Indianapolis46250 | NCT06855498 | Map |
| IN | Investigative Site US064 | West Lafayette47906 | NCT06855498 | Map |
| KS | Dermatology Skin Cancer Center Leawood | Leawood66211 | NCT07213973 | Map |
| KY | Equity Medical | Bowling Green42104 | NCT07213973 | Map |
| LA | Investigative Site US012 | Baton Rouge70809 | NCT06855498 | Map |
| LA | Investigative Site US057 | New Orleans70115 | NCT06855498 | Map |
| MD | Investigative Site US038 | Baltimore21287-0876 | NCT06855498 | Map |
| MD | Johns Hopkins Univ Schl of Medicine | Baltimore21205 | NCT07213973 | Map |
| MA | Investigative Site US030 | Boston02215 | NCT06855498 | Map |
| MA | Investigative Site US048 | Brighton02135 | NCT06855498 | Map |
| MI | Investigative Site US061 | Ann Arbor48103 | NCT06855498 | Map |
| MI | Oakland Hills Dermatology Pc | Auburn Hills48326 | NCT07213973 | Map |
| MI | Wayne State University Physician Group Dermatology | Detroit48201 | NCT07213973 | Map |
| MI | Investigative Site US091 | Troy48084 | NCT06855498 | Map |
| MI | Revival Research Institute, Llc Troy | Troy48084 | NCT07213973 | Map |
| MI | Investigative Site US042 | Waterford48328 | NCT06855498 | Map |
| MN | Axis Clinicals | Dilworth56529 | NCT07588139 | Map |
| MN | Investigative Site US011 | Minneapolis55455 | NCT06855498 | Map |
| MO | Investigative Site US088 | Saint Joseph64506 | NCT06855498 | Map |
| MO | Investigative Site US016 | St Louis63110 | NCT06855498 | Map |
| MO | Washington University | St Louis63110 | NCT07213973 | Map |
| MT | Boeson Research Missoula 2825 Fort Missoula Rd | Missoula59804 | NCT07213973 | Map |
| NH | Investigative Site US007 | Portsmouth03801 | NCT06855498 | Map |
| NM | University of New Mexico Hospital | Albuquerque87102 | NCT07213973 | Map |
| NY | Investigative Site US082 | East Syracuse13057 | NCT06855498 | Map |
| NY | Investigative Site US034 | New York10028-3135 | NCT06855498 | Map |
| NY | Investigative Site US065 | New York10128 | NCT06855498 | Map |
| NY | Investigative Site US081 | New York10075 | NCT06855498 | Map |
| NC | Investigative Site US031 | Chapel Hill27516 | NCT06855498 | Map |
| OH | Investigative Site US028 | Bexley43209 | NCT06855498 | Map |
| OH | Investigative Site US025 | Cincinnati45219 | NCT06855498 | Map |
| OH | Investigative Site US073 | Columbus43215 | NCT06855498 | Map |
| OK | Investigative Site US085 | Oklahoma City73170 | NCT06855498 | Map |
| PA | Investigative Site US069 | Plymouth Meeting19462 | NCT06855498 | Map |
| TX | Bellaire Dermatology Associates Bda | Bellaire77401 | NCT07213973 | Map |
| TX | Investigative Site US021 | Bellaire77401 | NCT06855498 | Map |
| TX | Investigative Site US010 | Dallas75246 | NCT06855498 | Map |
| TX | Investigative Site US078 | Dallas75230 | NCT06855498 | Map |
| TX | Texas Dermatology Research Center | Dallas75246 | NCT07213973 | Map |
| TX | Investigative Site US083 | San Antonio78218 | NCT06855498 | Map |
| TX | Investigative Site US068 | Webster77598 | NCT06855498 | Map |
| UT | Investigative Site US063 | South Jordan84095 | NCT06855498 | Map |
| UT | Jordan Valley Dermatology Center | South Jordan84095 | NCT07213973 | Map |
| VA | Investigative Site US027 | Norfolk23502 | NCT06855498 | Map |
| VA | Investigative Site US094 | Richmond23226 | NCT06855498 | Map |
| WA | Investigative Site US003 | Spokane99202 | NCT06855498 | Map |
Povorcitinib clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | Total |
|---|---|---|---|---|
| P1 | 1 | 4 | 5 | |
| P2 | 1 | 1 | 1 | 3 |
| P3 | 1 | 5 | 2 | 8 |
Recruiting Povorcitinib clinical trials (3)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07213973 | Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | P2 | Hidradenitis Suppurativa (HS) | 40 | Feb 2026 |
| NCT06855498 | STOP-LTRRollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | P3 | Hidradenitis Suppurativa (HS) | 600 | Feb 2025 |
| NCT07588139 | A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants | P1 | Healthy Participants | 24 | May 2026 |
Povorcitinib clinical trials by indication
Healthy Participants (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07588139 | — | P1 | recruiting | A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants |
| NCT06416800 | — | P1 | completed | A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants |
| NCT06505265 | — | P1 | completed | A Study to Evaluate Skin and Plasma Pharmacokinetic of Multiple Doses of Povorcitinib After Oral Administration in Healthy Participants |
| NCT06441318 | — | P1 | completed | A Study to Evaluate the Effect of Povorcitinib on the QT/QTc Interval in Healthy Participants |
| NCT06380205 | — | P1 | completed | A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult Females |
Hidradenitis Suppurativa (HS) (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07213973 | — | P2 | recruiting | Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa |
| NCT06855498 | STOP-LTR | P3 | recruiting | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib |
| NCT06212999 | STOP-HS LTE | P3 | active not recruiting | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa |
| NCT05620823 | STOP-HS1 | P3 | completed | A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa |
| NCT05620836 | STOP-HS2 | P3 | completed | A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS) |
Prurigo Nodularis (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06516965 | STOP-PN2 | P3 | active not recruiting | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) |
| NCT06516952 | STOP-PN1 | P3 | active not recruiting | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) |
NonSegmental Vitiligo (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06113471 | STOP-V2 | P3 | active not recruiting | A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2) |
| NCT06113445 | STOP-V1 | P3 | active not recruiting | A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1) |
Urticaria (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05936567 | — | P2 | completed | Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria |
Moderate to Severe Asthma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05851443 | — | P2 | active not recruiting | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma |
Povorcitinib pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| STOP-LTR | NCT06855498 | P3 | recruiting | Hidradenitis Suppurativa (HS) | 600 | — |
| STOP-PN2 | NCT06516965 | P3 | active not recruiting | Prurigo Nodularis | 346 | — |
| STOP-PN1 | NCT06516952 | P3 | active not recruiting | Prurigo Nodularis | 349 | — |
| STOP-V2 | NCT06113471 | P3 | active not recruiting | NonSegmental Vitiligo | 450 | — |
| STOP-V1 | NCT06113445 | P3 | active not recruiting | NonSegmental Vitiligo | 467 | — |
| STOP-HS LTE | NCT06212999 | P3 | active not recruiting | Hidradenitis Suppurativa (HS) | 617 | — |
| STOP-HS1 | NCT05620823 | P3 | completed | Hidradenitis Suppurativa (HS) | 608 | — |
| STOP-HS2 | NCT05620836 | P3 | completed | Hidradenitis Suppurativa (HS) | 619 | — |
All Povorcitinib trials (16)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07213973 | Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | P2 | recruiting | 40 | Incyte Corporation | Feb 2026 | |
| NCT06855498 | STOP-LTR | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | P3 | recruiting | 600 | Incyte Corporation | Feb 2025 |
| NCT05851443 | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma | P2 | active not recruiting | 247 | Incyte Corporation | Jul 2023 | |
| NCT06516965 | STOP-PN2 | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | P3 | active not recruiting | 346 | Incyte Corporation | Oct 2024 |
| NCT06516952 | STOP-PN1 | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | P3 | active not recruiting | 349 | Incyte Corporation | Oct 2024 |
| NCT06113471 | STOP-V2 | A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2) | P3 | active not recruiting | 450 | Incyte Corporation | Nov 2023 |
| NCT06113445 | STOP-V1 | A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1) | P3 | active not recruiting | 467 | Incyte Corporation | Nov 2023 |
| NCT06212999 | STOP-HS LTE | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | P3 | active not recruiting | 617 | Incyte Corporation | Jan 2024 |
| NCT07588139 | A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants | P1 | recruiting | 24 | Incyte Corporation | May 2026 | |
| NCT05620823 | STOP-HS1 | A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | P3 | completed | 608 | Incyte Corporation | Dec 2022 |
| NCT05620836 | STOP-HS2 | A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS) | P3 | completed | 619 | Incyte Corporation | Feb 2023 |
| NCT05936567 | Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria | P2 | completed | 136 | Incyte Corporation | Jul 2023 | |
| NCT06416800 | A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants | P1 | completed | 71 | Incyte Corporation | Jun 2024 | |
| NCT06505265 | A Study to Evaluate Skin and Plasma Pharmacokinetic of Multiple Doses of Povorcitinib After Oral Administration in Healthy Participants | P1 | completed | 18 | Incyte Corporation | Aug 2024 | |
| NCT06441318 | A Study to Evaluate the Effect of Povorcitinib on the QT/QTc Interval in Healthy Participants | P1 | completed | 128 | Incyte Corporation | Jul 2024 | |
| NCT06380205 | A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult Females | P1 | completed | 24 | Incyte Corporation | May 2024 |
Povorcitinib clinical trials: frequently asked questions
- How many Povorcitinib clinical trials are there?
- 16 Povorcitinib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 3 are actively recruiting participants. 7 are marked completed.
- Are Povorcitinib clinical trials recruiting in 2026?
- Yes — 3 Povorcitinib trials are actively recruiting in 2026, with 81 U.S. sites across 28 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Povorcitinib being studied for?
- Povorcitinib is being studied for Healthy Participants, Hidradenitis Suppurativa (HS), NonSegmental Vitiligo, Prurigo Nodularis, Moderate to Severe Asthma and 6 more. The trials are grouped by indication on this page.
- What phase is Povorcitinib in?
- Povorcitinib clinical trials span 8 Phase 3, 3 Phase 2, 5 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Povorcitinib clinical trials?
- The lead sponsor across the most Povorcitinib trials is Incyte Corporation. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Povorcitinibas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: